LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Multicenter Cohort Study of LORLATINIB-related HYPERLIPIDEMIA in ALK+ Advanced Non-Small Cell Lung Cancer Patients

The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days. The main question it aims to answer is:

• Whether blood lipids have been lowered down to an anticipated level within recommended range after the initial revealed Lorlatinib related hyperlipidemia?
• Will it be harmful to the cardiovascular system when blood lipids were not lowered down to normal levels in these cancer patients treated with Lorlatinib, i.e. major adverse cardiac events (MACE), or instead, carotid artery intima-media thickness.

Participants already taking Lorlatinib as part of their regular medical care for NSCLC will answer online survey questions.

Inclusion Criteria:

• Advanced ALK+ NSCLC diagnosed by patholgy and/or cytology
• ECOG 0-2
• Age 18-80 years
• Taken Lorlatinib for at least 20 days
• Signed informed consent.

Exclusion Criteria:

• Treatment with other anti-cancer drugs during Lorlatinib treatment